[
  {
    "ts": null,
    "headline": "Despite Slump, Options Traders May be Seeing Something with Quest Diagnostics (DGX)",
    "summary": "While DGX stock has been hammered in the market recently, the smart money may be sensing a bounce-back opportunity.",
    "url": "https://finnhub.io/api/news?id=68ee56fe0300e63d91fec238458c43f5b568e6b6f14ac10a4b3d8257bb776c3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752514202,
      "headline": "Despite Slump, Options Traders May be Seeing Something with Quest Diagnostics (DGX)",
      "id": 135932339,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "While DGX stock has been hammered in the market recently, the smart money may be sensing a bounce-back opportunity.",
      "url": "https://finnhub.io/api/news?id=68ee56fe0300e63d91fec238458c43f5b568e6b6f14ac10a4b3d8257bb776c3b"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics (DGX) Develops MCaST Blood Test with MD Anderson Cancer Center",
    "summary": "Quest Diagnostics Incorporated (NYSE:DGX) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 10, the company said it is developing a Multi-Cancer Stratification (MCaST) blood test in collaboration with The University of Texas MD Anderson Cancer Center. This initiative aims to improve the assessment of elevated cancer risk […]",
    "url": "https://finnhub.io/api/news?id=582f8ad4f02606e36e7e85483284f1a126bc759b0a947b855fff918fd3d1692f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752507057,
      "headline": "Quest Diagnostics (DGX) Develops MCaST Blood Test with MD Anderson Cancer Center",
      "id": 135928937,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics Incorporated (NYSE:DGX) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 10, the company said it is developing a Multi-Cancer Stratification (MCaST) blood test in collaboration with The University of Texas MD Anderson Cancer Center. This initiative aims to improve the assessment of elevated cancer risk […]",
      "url": "https://finnhub.io/api/news?id=582f8ad4f02606e36e7e85483284f1a126bc759b0a947b855fff918fd3d1692f"
    }
  }
]